Navigation Links
Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
Date:4/22/2009

Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer's Sutent, in combination with Bristol-Myers Squibb's Taxol, has advantages in this attribute over sales-leading Roche/Chugai's Avastin and Taxol.

The new report entitled Metastatic Triple-Negative Breast Cancer: Physicians Want More-Efficacious Therapies for This Niche CaB Population finds that a therapy that improves progression-free survival for patients would earn a 65 percent patient share in metastatic triple-negative breast cancer in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European oncologists.

In 2008, Decision Resources' proprietary clinical gold standard for metastatic triple-negative breast cancer was the combination of Avastin and Taxol. Based on available data and expert opinion, the combination of Sutent and Taxol will earn gold-standard status for metastatic triple-negative breast cancer in 2012, following Sutent's approval for the indication in 2010 in the U.S. and Europe.

"Physicians anticipate that the combination of Sutent and Taxol will be more effective than currently available therapies in improving progression-free survival," said Decision Resources Analyst Niamh Murphy, Ph.D. "Interviewed thought leaders indicate that Sutent has shown compelling preclinical data and they are encouraged by clinical trial results of Sutent monotherapy."

About the Report

Metastatic Triple-Negative Breast Cancer: Physicians Want More-Efficacious Therapies for This Niche CaB Population is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
9. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... La Sirena Foods provides premium canned seafood, ... and is looking to grow their market share in the USA. , "We are ... La Sirena Foods and indirectly with Otis McAllister , a leading ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic ... Western Championships. The competition will be held at the University of Montana on April ... west of the Mississippi River. , In order to qualify, Varize needed to place ...
(Date:4/28/2016)... TX (PRWEB) , ... April ... ... Interchange Standards Consortium (CDISC) announces today the open availability of a new ... platforms and catalogs for registering clinical trials. This innovative standard will make ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery community, announces ... section was recently revamped and upgraded to allow even more interaction between doctors and ... country. , According to the senior editor of Cosmetic Town, “We are excited that ...
(Date:4/28/2016)... Beach, FL (PRWEB) , ... April 28, 2016 , ... ... the spring season. Smart pots are frequently used by professional organic farmers and nurseries ... growers to order their supply of fabric pots. Our goal is to offer wholesale ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology: